Lytix Biopharma’s LTX-315 Shows Promising Trial Results

Lytix Biopharma AS (DE:6BG) has released an update.

Lytix Biopharma’s lead drug LTX-315 shows significant promise in treating basal cell carcinoma, with a Phase II trial demonstrating an 86% reduction in tumor size and a 51% complete clearance rate. The results position LTX-315 as a potential first-line therapy, bringing Lytix and its licensing partner Verrica Pharmaceuticals closer to commercializing the treatment for a market projected to reach USD 11.5 billion by 2028.

For further insights into DE:6BG stock, check out TipRanks’ Stock Analysis page.